Akebia股票維持買入評級,因CMS批准Vafseo付款決定H.C. Wainwright維持Akebia Therapeutics (NASDAQ: AKBA)的買入評級,目標價為7.50美元。

Post Content

Read More 

You may also like...

Generated by Feedzy